Selected article for: "clinical trial and immune response"

Author: Chattopadhyay, Saborni; Chen, Jui-Yi; Chen, Hui-Wen; Hu, Che-Ming Jack
Title: Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation
  • Document date: 2017_6_9
  • ID: 7q2wkwrf_12
    Snippet: Also belonging to the class of lipid-based nanoparticles are an emerging class of lipoplexes, which consist of cationic lipid derivatives for the complexation with nucleic acids [10, 51, 52] . Immunostimulatory RNAs or mRNAs encoding specific antigen targets have been formulated into lipoplexes to trigger immune responses. The function of these lipoplexes can be likened to the immune response induction by RNA viruses [53] . As RNAs are delivered .....
    Document: Also belonging to the class of lipid-based nanoparticles are an emerging class of lipoplexes, which consist of cationic lipid derivatives for the complexation with nucleic acids [10, 51, 52] . Immunostimulatory RNAs or mRNAs encoding specific antigen targets have been formulated into lipoplexes to trigger immune responses. The function of these lipoplexes can be likened to the immune response induction by RNA viruses [53] . As RNAs are delivered intracellularly by lipoplexes, they activate innate immune receptors, leading to an upregulation of type I interferons, which may further trigger a multitude of downstream immunological pathways [54] . Concurrently, these RNAs are translated into antigens of interest, thereby promoting an antigen-specific immune response. Lipoplexes carrying the mRNA of target antigens have recently been shown in a Phase I clinical trial to induce strong cellular responses against tumor antigens in humans [10] .

    Search related documents:
    Co phrase search for related documents
    • antigen specific immune response and clinical trial: 1
    • antigen specific immune response and immune receptor: 1
    • antigen specific immune response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antigen specific immune response and immune response induction: 1, 2, 3, 4
    • antigen target and cellular response: 1, 2, 3, 4, 5
    • antigen target and clinical trial: 1, 2, 3, 4, 5
    • antigen target and immune receptor: 1, 2, 3
    • antigen target and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antigen target and immune response induction: 1, 2, 3
    • cellular response and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • cellular response and immune receptor: 1, 2, 3, 4, 5, 6, 7, 8
    • cellular response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cellular response and immune response induction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cellular response and immune response trigger: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cellular response and innate immune receptor: 1, 2
    • clinical trial and human tumor antigen: 1
    • clinical trial and immune receptor: 1, 2, 3, 4, 5, 6, 7
    • clinical trial and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and immune response induction: 1, 2